Creative Medical Technology Holdings (CELZ) Retained Earnings (2010 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Retained Earnings of -$72.0 million for Q1 2026, down 8.7% year-over-year from -$78.9 million in Q1 2025, and down 1.99% quarter-over-quarter from -$70.6 million in Q4 2025.
Creative Medical Technology Holdings (CELZ) Retained Earnings (2010 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Retained Earnings for 17 consecutive years, with -$72.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 8.7% year-over-year to -$72.0 million; the TTM figure through Mar 2026 stood at -$72.0 million (down 8.7% YoY), while the FY2025 annual figure was -$70.6 million, down 199.51% from the prior year.
- Retained Earnings retreated to -$72.0 million in Q1 2026 per CELZ's latest filing, from -$70.6 million in the prior quarter.
- Across five years, Retained Earnings topped out at $70.9 million in Q4 2024 and bottomed at -$72.0 million in Q1 2026.
- Historically, Retained Earnings has averaged -$23.3 million across 5 years, with a median of -$56.0 million in 2023.
- On a YoY basis, Retained Earnings climbed as much as 259.56% in 2022 and fell as far as 223.84% in 2022.
- Creative Medical Technology Holdings' Retained Earnings stood at $69.7 million in 2022, then grew by 0.05% to $69.7 million in 2023, then advanced by 1.75% to $70.9 million in 2024, then plunged by 199.51% to -$70.6 million in 2025, then slipped by 1.99% to -$72.0 million in 2026.
- Business Quant data shows CELZ's Retained Earnings at -$72.0 million in Q1 2026, -$70.6 million in Q4 2025, and -$68.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Creative Medical Technology Holdings | 1.88 Mn | 1.88 Mn | - | 82.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 82.16 Mn |
| Mar 31, 2026 | -71.99 Mn |
| Dec 31, 2025 | -70.59 Mn |
| Sep 30, 2025 | -68.70 Mn |
| Jun 30, 2025 | -67.46 Mn |
| Mar 31, 2025 | -66.23 Mn |
| Dec 31, 2024 | 70.93 Mn |
| Sep 30, 2024 | -62.74 Mn |
| Jun 30, 2024 | 69.73 Mn |
| Mar 31, 2024 | -60.14 Mn |
| Dec 31, 2023 | 69.71 Mn |
| Sep 30, 2023 | -57.42 Mn |
| Jun 30, 2023 | -55.97 Mn |
| Mar 31, 2023 | -54.86 Mn |
| Dec 31, 2022 | 69.68 Mn |
| Sep 30, 2022 | -47.60 Mn |
| Jun 30, 2022 | -46.61 Mn |
| Mar 31, 2022 | 54.17 Mn |
| Dec 31, 2021 | -43.67 Mn |
| Sep 30, 2021 | 38.43 Mn |